Acadia Pharmaceuticals Inc. reported strong financial results for the fourth quarter and full year 2023, with total net product sales of $726.4 million, reflecting a 40% revenue growth. The company saw fourth quarter DAYBUE™ net product sales of $87.1 million and full year net product sales of $177.2 million, along with fourth quarter NUPLAZID® net product sales of $143.9 million and full year net product sales of $549.2 million. The company also highlighted advancements in its pipeline, including the initiation of Phase 3 trials for ACP-101 in Prader-Willi syndrome and ACP-204 in Alzheimer's disease psychosis. Acadia Pharmaceuticals is optimistic about its future prospects and is set to announce top-line results from the ADVANCE-2 study by the end of the first quarter.
Acadia Pharmaceuticals Inc. reported strong financial results...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.31 |
Change
-0.790(3.93%) |
Mkt cap ! $2.465B | |||
| Open | High | Low | Value | Volume |
| $19.86 | $19.99 | $17.97 | $22.67M | 1.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2222 | $19.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 8162 | 3 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.25 |
Change
-0.790 ( 4.18 %) |
||||
| Open | High | Low | Volume | ||
| $19.88 | $19.88 | $17.97 | 249066 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| NEU (ASX) Chart |